Inclusion Criteria

Inclusion Criteria Part A

- Participant has one of the selected solid tumors with no distant metastases, and is
more than 8 weeks from completion of definitive therapy with intention to cure and no
evidence of progressive disease on routine evaluations prior to enrollment (with the
exception for prostate carcinoma). Selected Solid Tumors: Stage I to III non-small
cell lung carcinoma (NSCLC); Stage III Breast Cancer; Stage IIB or III melanoma;
Stage II or III upper gastrointestinal tract carcinoma (e.g., esophagus, stomach,
gallbladder, pancreas); Stage III colon carcinoma; Stage II, III, or IV (M0 only)
renal cell carcinoma; Stage II, III, or IV (M0 only) bladder carcinoma;
clinically-localized prostate carcinoma in participants who have completed definitive
surgical resection and/or therapy no less than 8 weeks prior to protocol enrollment,
but now have a biochemical-only relapse with a rising serum prostate-specific antigen
(PSA) of >0.2 ng/mL after surgery or >1.5 ng/mL after radiation.

- Participant has an Eastern Cooperative Oncology Group (ECOG) performance status of 0
or 1.

- Participant has adequate organ function.

- Female participant of childbearing potential has a negative serum pregnancy test
within 3 days of study enrollment.

Exclusion Criteria Part A

- Participant has been previously treated with any human telomerase
reverse-transcriptase (hTERT)-containing/targeted vaccine or any prior adenoviral or
DNA vaccine.

- Participant is currently participating or has participated in a study with an
investigational compound or device within 30 days of signing informed consent.

- Participant has known hypersensitivity to any component of study vaccine.

- Participant has any laboratory value (with the exception of absolute lymphocyte
count) at the time of study entry and prior to the first vaccine administration that
would be considered Grade 3 or Grade 4 toxicity.

- Participant has a history of clinically significant cardiac conditions, including
cardiac arrhythmias which have not been controlled within the last 3 months, unstable
angina, myocardial infarction (within the last 3 months), or New York Heart
Association (NYHA) Class III or IV congestive heart failure. Participant must have no
clinically significant ECG abnormalities and not have a pacemaker or
cardioverter/defibrillator implanted.

- Participant has undergone splenectomy or has any history of autoimmune disorder.

- Participant has received immunosuppressive treatment (e.g., substances or treatments
known to diminish immune response such as radiation, antimetabolites, alkylators,
antilymphocytic sera, systemic corticosteroids) within 1 month prior to enrollment.
Topical hydrocortisone up to a concentration of ≤1%, as well as participants
receiving hormonal therapies (e.g., Lupron or Tamoxifen) or Herceptin, will be
allowed.

- Participant has known acquired, inherited, or idiopathic thrombocytopenia, platelet
dysfunction or coagulopathy that would contraindicate IM injections. Participant must
also have discontinued aspirin, NSAID, or any therapeutic warfarin or low molecular
weight heparin at least 2 weeks prior to enrollment. Participants on prophylactic
anticoagulant therapy such as low dose warfarin or heparin flush for in-dwelling
catheters, or low dose, cardiac-protective aspirin may be enrolled providing they
meet the coagulation entry parameters following discussion with the Sponsor.

- The presence of Coombs positive serology at the time of entry.

- Participant has an acute infection requiring intravenous antibiotic, antiviral or
antifungal agents within 2 weeks of study entry.

- Participant is pregnant or breastfeeding, or expecting to conceive at any time during
the study or within 1 year after receiving the last vaccination.

- Participant is known to be Human Immunodeficiency Virus (HIV)-seropositive.

- Participant has known history of Hepatitis B or C or active Hepatitis A.

- Participant has muscle group (deltoid, triceps, or thigh) that cannot be accessed
with a 1.27 cm (1/2") needle.

- Participant has been vaccinated for any disease or for prophylaxis within 1 month
prior to the first vaccination.

- Participant has any metal implants in the area of the injection site (e.g., shoulder
implant, in the upper arms or shoulder girdle).

- The participant has been diagnosed with Systemic Lupus Erythematosus (SLE) or has a
positive antinuclear antibody (ANA) titer and 1 of the following: positive
anti-double-stranded DNA antibodies, positive anti-Sm antibodies, or low C3 levels.
Participants with a positive ANA screen and/or a positive ANA titer only can be
admitted to the trial, if in the opinion of the Investigator, the participant does
not meet the American College of Rheumatology (ACR) diagnostic criteria for SLE.

- Participant with a history of a prior malignancy with the exception of cervical
intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated
localized prostate carcinoma with PSA <1.0; or who has undergone potentially curative
therapy with no evidence of that disease for five years, or who is deemed at low risk
for recurrence by his/her treating physician.

Inclusion criteria Part B

- Participant must have completed their respective vaccination Treatment Group regimen
for Part A of this study.

- Participant must have completed a ≥12 week safety observation period prior to
receiving their first DNA-EP boost.

- Prostrate cancer participants are allowed to have rising PSA levels.

- Participant is allowed to have local advancement of a pre-existing tumor lesion
documented in Part A of this study.

- Patient has an ECOG performance status of 0 or 1.

- Female participant of childbearing potential has a negative serum pregnancy test
within 3 days of Part B study enrollment.

Exclusion criteria Part B

- Participant has new or metastatic tumor lesions since enrollment in Part A.

- Participant has any laboratory value (with the exception of absolute lymphocyte
count) at the time of study entry and prior to the first vaccine administration that
would be considered Grade 3 or Grade 4 toxicity.

- Participant has developed any significant cardiac conditions since enrollment in Part
A including cardiac arrhythmias which have not been controlled within the last 3
months, unstable angina, myocardial infarction (within the last 3 months), or New
York Heart Association (NYHA) Class III or IV congestive heart failure.

- Participant must have no clinically significant ECG abnormalities and not have a
pacemaker or cardioverter/defibrillator implanted.

- Participant has undergone a splenectomy, or has developed any autoimmune disorders,
since enrollment in Part A.

- Participant has received immunosuppressive treatment (e.g., substances or treatments
known to diminish immune response such as radiation, antimetabolites, alkylators,
antilymphocytic sera, systemic corticosteroids) within 1 month prior to enrollment
for Part B. Topical hydrocortisone up to a concentration of ≤1%, as well as
participants receiving hormonal therapies (e.g., Lupron or Tamoxifen) or Herceptin,
will be allowed.

- Participant has developed any acquired, inherited, or idiopathic thrombocytopenia,
platelet dysfunction or coagulopathy that would contraindicate IM injections, since
enrollment in PART A. Participant must also have discontinued aspirin, NSAID, or any
therapeutic warfarin or low molecular-weight heparin at least 2 weeks prior to
enrollment in Part B. Participants on prophylactic anticoagulant therapy such as low
dose warfarin or heparin flush for in-dwelling catheters, or low dose,
cardiac-protective aspirin may be enrolled providing they meet the coagulation entry
parameters, following discussion with the SPONSOR.

- The presence of Coombs positive serology at the time of entry to Part B.

- Participant has an acute infection requiring intravenous antibiotic, antiviral or
antifungal agents within 2 weeks of entry to Part B.

- Participant has developed an interval history or current evidence of any condition,
therapy, or lab abnormality that might confound the results of the study, interfere
with the participant's participation for the full duration of the study, or is not in
the best interest of the participant to participate, since enrollment in Part A.

- Participant has developed a psychiatric or substance abuse disorder(s) that would
interfere with cooperation with the requirements of the trial since enrollment in
Part A.

- Participant is, at the time of signing informed consent for enrollment in Part B, a
regular user (including use of any illicit drugs or had a recent history (within the
last year) of drug or alcohol abuse.

- Participant is expecting to conceive at any time during the study or within 6 months
after receiving the last vaccination.

- Participant is known to be Human Immunodeficiency Virus (HIV)-seropositive.

- Participant has known history of Hepatitis B or C or active Hepatitis A.

- Participant has muscle group (deltoid, triceps, or thigh) that cannot be accessed
with a 1.27 cm (1/2" needle length).

- Participant has been vaccinated for any disease or for prophylaxis within 1 month
prior to the first vaccination.

- Participant has any metal implants in the area of the injection site (e.g., shoulder
implant, in the upper arms or shoulder girdle).

- Participant has been diagnosed with Systemic Lupus Erythematosus (SLE) or has a
positive ANA titer and 1 of the following: positive anti-double-stranded DNA
antibodies, positive anti-smooth muscle (Sm) antibodies, or low complement C3 levels,
since enrollment in Part A.